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Abstract
Although bone has a unique restorative capacity, i.e., it has the potential to heal scarlessly, the conditions for spontaneous
bone healing are not always present, leading to a delayed union or a non-union. In this work, we use an integrative in vivo -
in silico approach to investigate the occurrence of non-unions, as well as to design possible treatment strategies thereof.
The gap size of the domain geometry of a previously published mathematical model was enlarged in order to study the
complex interplay of blood vessel formation, oxygen supply, growth factors and cell proliferation on the final healing
outcome in large bone defects. The multiscale oxygen model was not only able to capture the essential aspects of in vivo
non-unions, it also assisted in understanding the underlying mechanisms of action, i.e., the delayed vascularization of the
central callus region resulted in harsh hypoxic conditions, cell death and finally disrupted bone healing. Inspired by the
importance of a timely vascularization, as well as by the limited biological potential of the fracture hematoma, the influence
of the host environment on the bone healing process in critical size defects was explored further. Moreover, dependent on
the host environment, several treatment strategies were designed and tested for effectiveness. A qualitative
correspondence between the predicted outcomes of certain treatment strategies and experimental observations was
obtained, clearly illustrating the model’s potential. In conclusion, the results of this study demonstrate that due to the
complex non-linear dynamics of blood vessel formation, oxygen supply, growth factor production and cell proliferation and
the interactions thereof with the host environment, an integrative in silico-in vivo approach is a crucial tool to further
unravel the occurrence and treatments of challenging critical sized bone defects.
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Introduction
Although bone has a unique restorative capacity, i.e. it has the
potential to heal scarlessly, the conditions for spontaneous bone
healing are not always present, leading to a delayed union or a
non-union. The orthopedic literature does not specify a universally
accepted definition of a fracture non-union [1,2]. The eventual
bony union after an atypical long period of healing, in comparison
to the normal healing period, is called a delayed union. The
absence of healing during at least three to six months defines a
fracture non-union in humans. Fracture non-unions (hypertrophic,
atrophic or oligotrophic) are classified based on their radiographic
and histological appearance [1,3].
Hypertrophic non-unions are characterized by an abnormal
vascularity and abundant callus formation. They are typically
caused by excessive motion at the fracture site, which prevents
bony bridging although the essential biological factors are present
[1]. Atrophic non-unions, however, are the result of inadequate
biological conditions and typically appear on radiographs as
blunted bony ends. They show little callus formation around the
fracture gap, filled with mostly fibrous tissue and little or no
evidence of mineral deposition [1]. Oligotrophic non-unions have
some radiographic and biological characteristics of both hyper-
trophic and atrophic non-unions, i.e. they possess the required
biological activity but show little or no callus formation [4].
Excess motion, a large interfragmentary gap [5], open fracture
[5–7], the particular bone [8], location of the trauma within the
bone [8], loss of blood supply [9], severe periosteal and soft-tissue
trauma [6,7] are some of the mechanical and biological risk factors
for the development of a non-union. Preexisting patient risk factors
such as old age [10], cachexia and malnutrition [11], immune
compromise [12], genetic disorders (e.g. type 1 neurofibromatosis),
osteoporosis [13], anticoagulants [14], anti-inflammatory agents
[15], etc. may also affect the fracture healing outcome but are not
the primary causes [16]. Besides an extensive amount of experi-
mental research, several computational models have also been
developed to further unravel the occurrence of fracture non-unions.
For comprehensive reviews on mathematical models of fracture
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healing, we refer the reader to Geris et al. [17], Isaksson et al. [18]
and Pivonka et al. [19]. Despite the large amount of (often
phenomenological) information existing in the literature, additional
in vivo, in vitro and in silico research is still required to address the
key mechanisms that lead to fracture non-unions, determine the
factors predictive of fracture complications and establish the optimal
therapeutic strategies for each type of fracture non-union.
In this work we propose an integrative in vivo - in silico
approach to investigate the occurrence of oligotrophic and
atrophic non-unions as well as to design possible treatment
strategies thereof. The gap size of the domain geometry of a
previously published mathematical model has been enlarged in
order to study the complex interplay of blood vessel formation,
oxygen supply, growth factors and cell proliferation on the final
healing outcome in large bone defects. The simulation results are
corroborated by comparison with dedicated experimental data.
Next, the mathematical model is used to explain the underlying
mechanisms that lead to the experimental observations as well as
design different treatment strategies. Finally, the potential of the
combined in silico - in vivo approach is demonstrated by applying
it to the case of BMP-treated fracture healing.
Materials and Methods
Ethics statement
All animal experiments were conducted according to the
regulations and with approval of the Animal Ethics Committee of
the KU Leuven.
Animals and operative procedure
C57BL/6 mice were purchased from the R. Janvier Breeding
Center (France). A segmental defect was created in the right tibia
of 14 week-old male mice as described elsewhere [20]. Briefly,
animals were anaesthetized with a ketamine-xylazine mixture
(100 mg/kg ketamine and 15 mg/kg xylazine) and the right lower
leg was shaved. A custom-made external fixator, based on the
Ilizarov external fixation device, was fixed to the tibia using 27 G
steel needles. Subsequently, the tibia was exposed and a 4.5–5 mm
mid-diaphyseal segment was excised with a 6.5 mm diamond saw
disk (Codema n.v., Kortrijk, Belgium). A demineralized CopiOs
scaffold (2.562.565 mm3; Zimmer b.v.b.a., Wemmel, Belgium)
seeded with 16106 mouse periosteal cells (passage 4) was
implanted, the skin was sutured and animals received postoper-
ative analgesia (buprenorphine, 60 mg/kg body weight). The
demineralized CopiOs- scaffold was used to minimize the soft
tissue collapse within the critical size defect. After 3, 14 or 56 days
animals were sacrificed, the tibia was excised and samples were
analyzed by mCT and then processed for histology.
Isolation and culture of murine periosteum-derived cells
Murine periosteum-derived cells (mPDC) were isolated from the
long bones of 8 week-old male mice as previously described [21]. In
short, the femurs and tibias isolated from 8 week old male C57BL/
6J mice were dissected and digested with collagenase-dispase after
protecting the epiphyses with low melting point agarose. After a
filtration and washing step, the cells were plated at 16104 cells per
square centimeter and replated when reaching 80–90% confluency.
After isolation, cells were pooled per 2–3 mice and cultured in a
humidified incubator at 37uC with 5% CO2 in a-minimal essential
medium (a-MEM) supplemented with 2 mM glutaMAX-I, 1%
penicillin/streptomycin (100 units/ml and 100 mg/ml respectively)
and 10% fetal bovine serum (all from Gibco, Life Technologies,
Gent, Belgium). When reaching 80–90% confluency, cells were
trypsinized and reseeded at 7500 cells/cm2.
Transduction of mPDC
To deliver BMP2 at the defect site, mPDCs were transduced
72 hours prior to implantation with an adenoviral vector encoding
human BMP2 (a generous gift from Dr. Frank Luyten, KU
Leuven, Belgium) at a multiplicity of infection of 50.
Radiographic and mCT analyses
Bone formation in large bone defects was followed by
radiographic images at different time points after surgery using
the Skyscan 1076 high resolution in vivo micro-computed
tomography (mCT) scanner (Bruker-mCT, Kontich, Belgium).
For bone quantification, samples retrieved at day 56 were scanned
using the high resolution SkyScan 1172 mCT system (Bruker-mCT)
at a pixel size of 10 mm with 50 kV tube voltage and 0.5 mm
aluminum filter. Projection data was reconstructed using the
NRecon software and quantification of mineralized tissue was
performed using the CTAn software (both from Bruker-mCT).
Histology and immunohistochemistry
Isolated bones were fixed in 2% paraformaldehyde overnight and
decalcified in EDTA for 14 days at 4uC prior to dehydration,
embedded in paraffin and sectioned at 4 mm. Histochemical staining
with hematoxylin and eosin (H&E) and immunohistochemical staining
for mouse CD31 is routinely performed in our lab and has been
described previously [21]. Images were taken on a Zeiss Axioplan 2
light microscope using the Zeiss AxioVision software.
Statistical analysis
Data are presented as means 6 standard error of the means.
Data were analyzed by one-way ANOVA using the NCSS
statistical software. Differences were considered statistically
significant at p,0.05.
Mathematical model
The multiscale computational framework for the mathematical
modelling of bone fracture healing and its relation to angiogenesis
Author Summary
In 5–10% of fracture patients, the bone fractures do not
heal in the normal healing period (delayed healing) or do
not heal at all (non-union). In order to investigate the
causes of impaired healing and design potential treatment
strategies, we have used a combined experimental and
computational approach. More specifically, large bone
defects were analyzed in mouse models and simulated by
a previously published computational model. After show-
ing that the predictions of the computational model
match the observations of the experimental model, we
have used the computational model to investigate the
underlying mechanisms of action. In particular, the results
indicated that the new blood vessels do not reach the
central fracture zone in time due to the large defect size,
which leads to insufficient oxygen delivery, increased cell
death and disrupted bone healing. The healing, however,
could be rescued by adequate blood vessel ingrowth from
the overlying soft tissues. Moreover, potential treatment
strategies were designed based on the influence of these
soft tissues. In conclusion, this study demonstrates the
potential of a combined experimental and computational
approach to contribute to the understanding of patho-
logical processes like the impaired bone regeneration in
large bone defects and design future treatments thereof.
A Combined In Vivo-In Silico Approach to Treat Large Bone Defects
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was established earlier and has been described in detail in [22].
The framework consists of (1) a tissue level describing the various
key processes of bone fracture healing with 10 continuous
variables, (2) a cellular level representing the developing vascula-
ture with discrete endothelial cells and (3) an intracellular level that
defines the internal dynamics of the Dll4-Notch signaling pathway
in every endothelial cell (Figure 1). The model accounts for the
various key processes that occur during the soft and hard callus
phase of bone fracture healing (see [22] for a more detailed
description). While the model described in [22] already partially
accounted for the role of oxygen, we have recently extended the
model to capture the various effects of oxygen on cellular processes
in a much more complete and refined way [23]. A brief
description of the oxygen model is found below and more details
are given in Supporting Text S1.
After the initial inflammation phase (which is not included in the
current mathematical model), the fracture callus is filled with a
cocktail of granulation matrix, stem cells and growth factors. In
regions where oxygen is abundantly available (i.e. close to the
cortex in the case of normal fracture healing), the mesenchymal
stem cells will directly differentiate into osteoblasts and form bone
through the intramembranous pathway. In regions where the
oxygen tension is lower (i.e. the central fracture callus in the case of
normal fracture healing), the mesenchymal stem cells will
differentiate to chondrocytes that will form a cartilage template
to mechanically stabilize the fracture. This is followed by
endochondral ossification during which blood vessels and osteo-
blasts are attracted to the central fracture callus, resulting in
degradation of the cartilage template and bone formation. Finally,
the newly formed bone is remodeled (not included in the current
mathematical model).
At the tissue level, the fracture healing process is described by
calculating the spatiotemporal evolution of the density of
mesenchymal stem cells (cm), osteoblasts (cb), chondrocytes (cc),
fibroblasts (cf), bone (mb), cartilage (mc), fibrous matrix (mf),
osteochondrogenic growth factor (gbc), angiogenic growth factor
(gv) and oxygen (n) using 10 non-linear, coupled partial differential
equations of the taxis-diffusion-reaction type. At the cellular level,
the evolution of the discrete vasculature is determined by
sprouting, vascular growth and anastomosis and is modeled by a
lattice-free method. At the intracellular level, an agent-based
model is used to implement the rules that capture the intracellular
dynamics of the Dll4-Notch signaling pathway which determines
tip cell selection during sprouting angiogenesis. The oxygen model
Figure 1. Schematic representation of the multiscale oxygen model. m=mf+mc+mb represents the total tissue density. The intracellular
variables govern the endothelial cell (EC) behavior. At the tissue scale, cells can migrate (only MSCs and fibroblasts), proliferate (circular arrows),
differentiate (vertical arrows), produce growth factors and extracellular matrix. Blood vessels are a source of oxygen which influences proliferation,
differentiation and hypoxia-dependent angiogenic growth factor production. Variables influencing a tissue level process are indicated next to the
corresponding arrow.
doi:10.1371/journal.pcbi.1003888.g001
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includes an accurate description of the oxygen dependency of a
number of cellular processes, namely osteogenic and chondrogenic
differentiation, cell proliferation, cell death, oxygen consumption
and the hypoxia-dependent production of an angiogenic growth
factor. The cellular consumption of oxygen was described using a
Michaelis-Menten kinetic law where the cell-specific maximal
oxygen consumption rate has the following relative cellular order:
chondrocytes,MSCs,osteoblasts,fibroblasts. The oxygen values
at which the considered cell-specific oxygen-dependent processes
occur at maximal rate or at which their rate changes are based on
a rigorous literature screening of the state-of-the-art experimental
knowledge (Figure 2). More specifically, the relative order of the
oxygen dependent processes was determined as accurately as
possible since it is crucial to the behavior of the oxygen model. The
complete description of the set of equations, the boundary and
initial conditions, the parameter values, implementation details as
well as some underlying assumptions and simplifications can be
found in Supporting Text S1 as well as in previous publications
[22,24,25].
The geometrical domain of the fracture callus, as well as the
boundary conditions and initial positions of the endothelial cells
(cv) are shown in Figure 3-B. Note that the periosteum near the
bone ends is considered to be well vascularized such that a
muscular contribution to the vasculature (i.e. the initial position of
the endothelial cells) is unnecessary. To simulate the bone
regeneration process in a large bone defect, the domain was
extended over a distance equal to half the gap size of a murine
critical sized defect (5 mm). The effect of the host environment on
the fracture healing process is explored with several combinations
of boundary conditions, however in the standard compromised
condition the influence of the host environment is neglected
thereby representing the worst-case scenario (Figure 3-B). It has
been shown experimentally that the amount of cells and growth
factors is significantly reduced in a large fracture gap [26,27].
Therefore, in order to simulate this effect, the initial conditions for
the MSCs and osteochondrogenic growth factors were decreased
tenfold to 2.103 cells/ml and 10 ng/ml respectively in the central
callus area (indicated with dots in Figure 3-B). The initial oxygen
tension (ninit) in the central callus area is equal to 3.7%. All other
model parameters as well as initial and boundary conditions were
left unchanged with respect to the normal healing case [23] and
can be found in Supporting Text S1 (Figure 3). Note that the
computational model does not simulate the presence of the
demineralized CopiOs scaffold, which was used to minimize the
soft tissue collapse within the critical size defect. Previous results
have however shown that the demineralized carrier structure does
not contribute nor enhance the bone formation process.
The results of the mathematical model are quantified in terms of
tissue fractions, specified for each part of the fracture callus (i.e.
endosteal, periosteal and intercortical). The tissue fractions are
calculated by the following procedure: first the spatial images are
binarized using tissue-specific thresholds (0 means that the tissue is
not present, 1 means that the tissue is present in a grid cell).
Subsequently, an equal weight is assigned to the different tissues,
i.e. if a grid cell contains three tissues, the area of that grid cell is
divided by three in the final calculations of the tissue (area)
fractions [23].
Results
In silico and in vivo non-union model
A qualitatively similar healing progression is predicted by the
simulation results as observed experimentally (Figures 4 and 5). At
early time points a periosteal reaction, characterized by a
thickening of the periosteal layer (Figures 5-B1, B19 and C1) as
well as the presence of a hematoma, a fibrous-like tissue associated
with the presence of numerous (red) blood cells (Figures 5-B1,
B10), are observed at the cortical host bone site, both supporting
the initial and boundary conditions that were applied in the
multiscale model (Figure 3-B). In the center of the large bone
defect no signs of tissues or infiltration of blood vessels are
detected, only scaffold material together with a low cellularity is
observed (Figures 5-B1-center, C19), corresponding to the predic-
tions of the in silico model (Figure 4-G).
On day 14, a periosteal endochondral ossification reaction is
seen, evidenced by the presence of cartilage (large round cells
staining grey-blue with H&E) and trabecular-like bone (dense
matrix, staining bright pink with H&E, with the clear presence of
embedded osteocytes) (Figures 5-B2, B29; arrow indicates carti-
lage), while direct bone formation occurs endosteally (Figures 5-
B2, B20). The mathematical model predicts a similar distribution
of tissue formation, i.e. direct bone formation near the bony ends
and endochondral ossification further away in the fracture callus
(Figure 4-B,C). In the center of the defect only a highly dense
fibrous tissue is observed in both the experimental, the scaffold
remains stained pink-blue with H&E but lack the presence of
embedded cells (Figure 5-B2-center), as well as the mathematical
model (Figure 4-A). In contrast to the experimental model, the
mathematical model does not predict any blood vessels in the
central callus area (indicated with dots in Figure 3). These vessels,
however, appear to be small and immature whereas the blood
vessels that are associated with the sites of bone formation are large
and mature (compare Figures 5-C2 and C29). This discrepancy
might be explained by the fact that the mathematical framework
only models angiogenesis, i.e. blood vessel growth through the
creation of new vessel branches from existing ones, whereas
vasculogenesis, i.e. de novo network formation from scattered
endothelial cells, is not included here. Indeed, after bone fracture
the hematoma will be filled with blood, containing amongst others
endothelial precursor cells, which could explain the small,
immature blood vessels observed experimentally. We would like
to stress, however, that this is a first hypothesis that is currently
being explored further.
Notice the closure of the bone marrow canal by new bone on
day 56, separating the bone marrow (right) from the scaffold
region (left) (Figure 5-B3, B39, B30). As such, capping of the
bone ends has occurred both in the experimental and the
mathematical model (Figure 4-C). The blood vessels in the
center are still much smaller compared to those near the edges
of the defect (compare Figure 5-C3 and C39). In the center of
the defect no signs of bone formation are detected, only fibrous
tissue is seen, at this time point associated with a very low
cellular content (Figure 5-B3-center). Also in the mathematical
model no additional bone formation is predicted between post
fracture day (PFD) 60 and 90, thereby classifying this fracture
as a non-union [1,2].
After this qualitative validation of the model predictions with
the experimental observations of bone healing in a large defect, the
model was used to understand the mechanisms underlying the
occurrence of fracture non-unions. It appears that in the
mathematical model, chondrogenic differentiation and cell
survival are severely impaired in the central callus area (indicated
with dots in Figure 3) due to the harsh hypoxic conditions (optimal
oxygen tension for chondrogenic differentiation is 3%, minimal
oxygen tension for MSC and chondrocyte survival is 0.5%, see
Figure 2) (Figure 4-D,F). Consequently, the angiogenic growth
factor (gv), which is the major stimulus for vascular growth and as
such endochondral ossification, is not produced in the central
A Combined In Vivo-In Silico Approach to Treat Large Bone Defects
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callus area (Figure 4-E). As a result, the bone healing stops after
capping of the bony ends, resulting in an atrophic non-union
(Figure 4-C). Note that the predicted bone front extents further
into the callus than observed in the in vivo model. This might be
due to some limitations of the computational model. Firstly, in the
current model all the progenitor cells can differentiate towards
both the chondrogenic and osteogenic lineage, depending on the
local growth factor concentrations and oxygen tensions. In reality,
however, it has been shown that the progenitors from the
endosteal callus can only differentiate towards the osteogenic
lineage, resulting in the absence of cartilage in the endosteal callus
[28]. Progenitor cells from the periosteum do have the capability
to differentiate to both lineages, explaining why endochondral
ossification mainly occurs in the periosteal callus [28]. As such, the
current simplification of the model leads to an overestimation of
the amount and the location of the cartilage matrix, resulting in an
overestimation of the predicted bone formation. Secondly, the
current model does not account for changes in callus size and
shape during the healing process which may also influence the
bone formation process.
Figure 2. Overview of the oxygen tensions at which the rate of distinct cellular processes is maximal or changes. Biological processes
that preferentially take place in low oxygen tensions (upper part of Figure 2) will occur in regions where the oxygen tensions will have dropped with
respect to the initial value (e.g. the central fracture zone) while biological processes that preferentially take place in high oxygen tensions (lower part
of Figure 2) will occur in regions where the oxygen tensions will have increased with respect to the initial value (e.g. near the blood vessels of the
periosteal layer). The initial oxygen tension in the central fracture zone is 3.7%.
doi:10.1371/journal.pcbi.1003888.g002
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The defect size of murine bone fractures becomes critical
at 3 mm
After establishing the in silico and in vivo non-union model, the
in silico model was further used to explore the influence of the gap
size on the healing outcome (Figure 6). By increasing the gap size,
the bone tissue fraction at PFD 90 is reduced whereas the cartilage
fraction remains similar (close to zero) and the fibrous tissue
fraction is greatly increased (Figure 6). Although the bone tissue
fraction reaches 84% in a 3 mm defect, there is no cortical
bridging which indicates the formation of a non-union. The
simulation therefore predicts that a murine bone defect becomes
critical at 3 mm. In the remaining part of this study we will focus
on the bone regeneration process in 5 mm defects, in correspon-
dence with the in vivo set-up described above.
The biological potential of the fracture callus is necessary
but insufficient for complete bone healing
Since for all the different gap sizes explored in Figure 6, the
same set of initial and boundary conditions was employed, the
occurrence of fracture non-unions might be attributed to an
Figure 3. Geometrical domain and boundary conditions of the computational model. (A) The geometrical domain considers one-fourth of
the real fracture callus geometry of a critical size defect (assuming symmetry); 1 periosteal callus; 2 intercortical callus; 3 endosteal callus; 4 cortical
bone ends. (B) No-flux boundary conditions are assumed for all variables, except for the mesenchymal stem cells (cm) and fibroblasts (cf) which are
released from the periosteum and surrounding soft tissues near the bony ends as well as the bone marrow [55]; and the osteochondrogenic growth
factor (gbc) which is released from the degrading bone ends and the cortex [56,57]. The central callus area (indicated with dots) is initialized with a
reduced amount of cells (cm,init= 2.10
3 cells/ml) and growth factors (gbc,init=10 ng/ml) with respect to the tissues surrounding the bone end
(cm,init= 2.10
4 cells/ml, gbc,init= 100 ng/ml). The initial oxygen tension (ninit) in the central callus area is 3.7%. The origin of the coordinate system is
placed in the left bottom corner of the geometrical domain.
doi:10.1371/journal.pcbi.1003888.g003
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inadequate vascularization of the central callus region. More
specifically, the ingrowing vasculature which originates from the
bony ends, needs to cover a larger distance in larger defects,
resulting in a too late vascularization of the central fracture area
(Figure 4-G) and consequently harsh hypoxic conditions (Figure 4-
F). As was explained above, these hypoxic conditions lead to cell
death thereby arresting the production of angiogenic growth
factors and ultimately the bone healing process (Figure 4-C).
Clearly, the spatiotemporal patterns of oxygen tension are an
important determinant of successful bone repair which prompted
us to investigate the complex interplay between oxygen delivery,
diffusion and consumption in a critical size defect (5 mm). An
extensive sensitivity analysis was performed on the parameter
values describing the delivery of oxygen (Gn), the diffusion of
oxygen (Dn) and the oxygen consumption by osteoblasts (Qb),
chondrocytes (Qc), MSCs (Qm) and fibroblasts (Qf). Moreover,
since experimental evidence has shown that the biological
potential (e.g. the amount of osteoprogenitor cells and growth
factors present) might be greatly reduced in critical size defects
[26,27], we also explored the influence of the initial conditions
(cm,init, gbc,init, cf,init, mf,init, ninit) in the central callus area
(indicated with dots in Figure 3) on the fracture healing outcome
(Table S1 in the supplementary material).
The initial position of the endothelial cells (see Figure S1 in the
supplementary material), has a small influence on the final bone
tissue fraction (+/22%). This difference can be attributed to a
different spatial filling of the blood vessels in the 2D simulated
geometry and is in the same range as the influence of the stochastic
component in the description of blood vessel migration on the
simulation outcome (+/23%) [24]. Based on these findings, we
consider deviations of more than 2% with respect to 50% of bone
tissue fraction to be sufficient to warrant further analysis. In order to
gain more understanding in the complex non-linear dynamics of the
oxygen model, the mechanisms underlying these significant
deviations were investigated and are discussed in more detail below.
The sensitivity analysis revealed a non-linear influence of the
initial amount of MSCs (cm,init) on the bone tissue fraction at PFD
90. This can be explained by the fact that on the one hand a low
initial concentration of MSCs (cm,init,2.10
4 cells/ml) reduces the
biological potential of the fracture site since less cells can
contribute to the bone healing process. On the other hand, a
high initial concentration of MSCs (cm,init.2.10
5 cells/ml) will
Figure 4. The predicted spatiotemporal evolution of fracture healing in a critical sized defect (5 mm). (A) fibrous tissue density (60.1 g/
ml), (B) cartilage matrix density (60.1 g/ml), (C) bone matrix density (60.1 g/ml), (D) chondrocyte density (6106 cells/ml), (E) angiogenic growth factor
(GF) concentration (6100 ng/ml), (F) oxygen tension (61%) and (G) active vasculature.
doi:10.1371/journal.pcbi.1003888.g004
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worsen the detrimental hypoxic conditions in the central callus
region due to the increased amount of oxygen consumption. The
initial concentration of fibroblasts (cf,init) does not show this non-
linear behavior. High initial concentrations of fibroblasts and/or
MSCs are detrimental (cf,init.5.10
5 cells/ml) since the increased
oxygen consumption will lower the average oxygen tension in the
central callus area. Contrary to the MSCs, low initial concentra-
tions of fibroblasts do not seem to have a major influence on the
final amount of bone formation. This is mainly because fibroblasts
do not contribute to the biological potential of the hematoma as
they cannot differentiate towards the osteogenic or chondrogenic
lineage.
Figure 5. Analysis of healing of large bone defects in the tibia of mice in which a collagen scaffold seeded with periosteal cells was
implanted. (A) Radiographic images of the treated defects (5 mm gap size) showing capping (arrows) of the cortical bone ends, but absence of full
defect healing over the course of 56 days. (B–C) Images of H&E (B) and CD31 (C) stained histological sections of treated bone defects obtained at 3, 14
or 56 days after surgery. H&E provides a general image of the tissues under investigation whereas CD31 specifically stains the blood vessels. The
arrow in B29 indicates cartilage remnants adjacent to new bone tissue. Scale bars: 200 mm and 100 mm (9,0)in B, 100 mm in C. b: cortical bone, p:
periosteal region, e: endosteal region, s: scaffold.
doi:10.1371/journal.pcbi.1003888.g005
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The sensitivity analysis also indicates that the amount of
osteochondrogenic growth factors present in the fracture hema-
toma (gbc,init) is a critical determinant of the final amount of bone
formation. Indeed, increasing the growth factor concentration
results in a significant increase in the amount of bone formation
measured after 90 days of healing. This result can be attributed to
an increased chondrogenic differentiation which limits the oxygen
consumption since chondrocytes consume less oxygen than MSCs.
As such, the central hypoxic area will be reduced leading to more
bone formation.
After the inflammation phase, the fracture callus is filled with
granulation tissue (represented here by mf,init). It appears that a
large amount of granulation tissue negatively influences the
fracture healing outcome which is due to its inhibitory effect at
large matrix densities on the proliferative capacities of MSCs,
fibroblasts, chondrocytes and osteoblasts.
Similar to the initial amount of MSCs also the initial oxygen
tension (ninit) has a non-linear effect on the final amount of bone
formation. Very low oxygen tensions (ninit,0.5%) lead to a larger
hypoxic area and less bone formation whereas oxygen tensions
above 4% (ninit.4%) hamper the proliferation of chondrocytes,
thereby disrupting the cartilage production and consequently the
endochondral ossification process. Interestingly, in the intermedi-
ate range of oxygen tensions (0.5%,ninit,4%), lower initial
oxygen tensions appear to result in more bone formation (Table
S1, 0.7% versus 3.7% oxygen tension of the standard compro-
mised condition). Although intuitively we would expect that these
low oxygen tensions would lead to worse hypoxic conditions,
model analyses show that the average oxygen tension in the
fracture callus remains above 0.8% during the entire healing
period (note that the low oxygen tensions of the central callus area
are averaged with the high oxygen tensions near the bony ends),
which is well above the oxygen threshold for chondrocyte and
MSC cell death (i.e. 0.5%). As such the oxygen tension is low
enough to inhibit extensive proliferation (as the chondrocytes and
MSCs preferentially proliferate at 3% and 4% oxygen tension
respectively, Figure 2) and therefore avoiding too much oxygen
consumption, but high enough to keep a small amount of
remaining stem cells alive. Moreover, the oxygen consumption is
not only reduced due to the smaller amount of consuming cells.
The cellular consumption of oxygen is also oxygen dependent,
leading to a lower cellular consumption in low oxygen environ-
ments. It is the combination of these effects that limits the drop of
the average oxygen tension, allowing the MSCs to survive and
contribute to the bone healing process for a longer period of time
(40 days for case ninit=0.7% versus 4 days in the standard
condition). A similar reasoning can be made for the case where an
initial gradient of oxygen tensions was applied to the central callus
Figure 6. Predicted tissue fractions at post fracture day (PFD) 90 in bone defects of varying sizes. The 5 mm defect size will be further
investigated in the remaining part of this study. The femurs at the right hand side of the figure schematically represent the bone healing outcome at
PFD 90, i.e. the formation of a union or a non-union.
doi:10.1371/journal.pcbi.1003888.g006
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region (ninit,gr=0.8%/mm*x). In this simulation the oxygen
tension varied from 0% in the middle of the callus to 4% at the
bony ends. The low oxygen tensions in the central area supported
the maintenance of a small population of MSCs for a longer
period of time (6 days versus 4 days in the standard condition).
This resulted in a larger amount of cartilage and finally bone. Note
that this specific gradient in oxygen tension is less beneficial for the
amount of bone formation at PFD 90 than a uniform distribution
of 0.7%, as in the case of the gradient the oxygen tension in the
middle of the callus is too low to sustain cell viability.
Besides investigating the influence of the initial conditions, the
sensitivity analysis also focused on the complex interplay between
oxygen delivery (Gn), diffusion (Dn) and consumption (Qb, Qc, Qm,
Qf). Altering the oxygen delivery (Gn) by the vasculature has a
large effect on the final amount of bone formation. Very low
values of oxygen delivery increase cell death in the central hypoxic
area, resulting in the absence of any bone formation. Increasing
the value of oxygen delivery slightly improves the fracture healing
outcome. Note that, although the bone tissue fraction is 37% in
case of Gn=22.10
212 mol/cell.day and 55% in case of
Gn=3.2.10
212 mol/cell.day, the spatial extent of bone ingrowth
at PFD 90 is very similar (results not shown). This is however
masked by the increased proliferation and matrix production of
fibroblasts who thrive in the well-oxygenated environment created
by Gn=22.10
212 mol/cell.day. As such, the bone tissue fraction
for Gn=22.10
212 mol/cell.day is reduced with respect to
Gn=3.2.10
212 mol/cell.day. The parameter values of the cell-
specific oxygen consumption rates (Qb, Qc, Qm, Qf) also influence
the outcome of the model significantly. For all cell types, it is
beneficial to reduce the oxygen consumption rates since this will
limit the decrease in oxygen tension in the central fracture area
and consequently the amount of cell death. This benefit is greatest
for the MSCs and chondrocytes as these cell types mainly populate
the central fracture area and contribute to the hypoxic conditions
encountered here. Conversely, the amount of bone formation is
greatly reduced when the oxygen consumption rate of the MSCs
(Qm) or chondrocytes (Qc) is increased. The model outcome is also
negatively affected by a high osteoblastic oxygen consumption rate
(Qb) whereas a high fibroblastic consumption rate (Qf) only slightly
reduces the final amount of bone. In the first case, the oxygen
tension near the bony ends is reduced, resulting in hampered
osteogenic differentiation and limited bone formation. In the latter
case, the fibroblasts reduce the oxygen tension in the entire callus
area (the fibroblasts are initially uniformly distributed in the
fracture callus) but this drop is limited due to the small amount of
fibroblasts present. Interestingly, a similar reasoning does not hold
for the MSCs (although they are also initially uniformly distributed
and limited in cell population) since they mainly grow in the
central fracture zone whereas the fibroblasts optimally proliferate
in a well-oxygenated environment such as the tissues surrounding
the bony ends. As such, a high oxygen consumption rate of MSCs
severely impairs the bone formation process whereas a high
oxygen consumption rate of fibroblasts only slightly reduces the
amount of bone formed at PFD 90.
It can be noticed from Table S1 and Figure S2 that the diffusion
properties of oxygen have a major impact on the simulation
outcome. Reducing the diffusion coefficient of oxygen impairs the
bone formation due to the creation of a larger hypoxic zone
(Figure S2-A,C). Increasing the diffusion coefficient appears to be
beneficial although a closer look at these simulation results reveals
that the endochondral process is not captured correctly anymore
with bone formation largely preceding the ingrowth of new blood
vessels (Figure S2-D,F). Note that also in this case a non-union is
formed, since there is no cortical bridging, even though a bone
tissue fraction of 89% is reached (Table S1). Increasing the
diffusion coefficient even further results in a complete absence of
bone formation since the resulting oxygen tensions are too low for
any cell type to survive (Figure S2-H) (see Supporting Text S3).
In conclusion, we can state that the initial conditions have an
important impact on the final amount of bone formation. They are
however not sufficient to result in complete healing of critical size
defects due to insufficient vascularization of the central callus area,
leading to hypoxic conditions and cell death. As such, an adequate
and timely restoration of the vasculature appears to be an
important determinant of the healing outcome.
Contribution of the muscle vasculature to the
vascularization of the fracture callus is beneficial for bone
healing
Inspired by the importance of a timely vascularization as well as
by the limited biological potential of the fracture hematoma, we
explored the influence of the host environment on the bone
healing process in critical size defects. It appears that the fracture
healing process is intimately linked to the surrounding muscle
envelope since clinical evidence has found that open fractures with
significant muscle injury complicate fracture healing and are a risk
factor for the development of non-unions [5–7]. Moreover, tibial
shaft fractures, which are only covered by a thin layer of soft tissue,
are prone to a number of complications often resulting in
additional surgical interventions [5,9,29]. There are a number of
ways by which the skeletal muscle can contribute to the bone
healing process. Firstly, experimental studies have shown that
blood vessels originating in the overlying muscle contribute to the
vascularization of the fracture callus [30,31]. Secondly, muscle
cells are a source of growth factors (e.g. FGF-2, TGF-b) [32] as
well as progenitor cells [33–35]. Thirdly, the muscle envelope
might provide the adequate biomechanical stimuli required for
successful bone healing [36,37].
In order to further unravel the potential mechanisms of
interaction that exist between the bone regeneration process and
the overlying skeletal muscle, the role of the skeletal muscle as a
source for vascularization, progenitor cells and growth factors or a
combination thereof was investigated by applying different
boundary conditions to the in silico model (Figure 7–8). More
specifically, the contribution of the muscle to the vascularization of
the fracture callus was simulated by initializing additional
endothelial cells on the border of the central callus area with the
muscle, either partially or fully covering the fracture gap. The
influence of the muscle as a source of MSCs or growth factors was
represented by a Dirichlet boundary condition, applied to the
upper border for the entire duration of the simulation (i.e. 90 days)
and fully covering the fracture gap (Figure 7). The value of the
Dirichlet boundary conditions is equal to the ones applied in the
standard case, i.e. 2.104 cells/ml for the MSCs and 2 mg/ml for
the osteochondrogenic growth factors [25,38–40]. Since the
mathematical model does not take into account any mechan-
oregulatory stimuli, the influence of mechanoregulatory stimuli
generated by the overlying muscle on the bone formation
processes cannot be evaluated in this study.
The results, summarized in Figure 8, underline the importance
of the host environment for successful fracture healing since all the
investigated conditions improve the amount of bone formation
with respect to the standard condition or result even in bridging of
the critical size defect. Note that the host environment is also more
efficient in stimulating the bone regeneration process than the
initial conditions tested in Table S1, since the host environment
continuously provides the fracture callus with fresh growth factors,
cells and blood vessels (or a combination thereof) whereas the
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initial conditions represent only a single (initial) contribution to the
bone regeneration process. In order to limit the length of the
paper, we will touch upon the most important findings of Figure 8
and refer the reader to Supporting Text S4 for an in depth
discussion of the results. Both the contribution of the muscle as a
source of vascularization (case A) as well as of osteoprogenitor cells
(case D) results in the formation of a union, whereas a partial
supply of blood vessels from the host environment (case B) or
muscle derived release of osteochondrogenic growth factors fails to
result in a complete bridging of the defect (Figure S3). In most
cases, except for cases E and G, the combination of two or more
boundary conditions enhances the bone formation process.
Indeed, the combined delivery of cells and growth factors results
in less bone formation (case E) than the delivery of cells alone (case
D). Figure 8 also shows that without vascular ingrowth from the
muscular environment, the delivery of cells results in the largest
amount of bone formation (case C versus case D). However, if the
fracture callus is fully or partially vascularized by the overlying
muscle, the delivery of growth factors is more beneficial than the
delivery of cells for the final healing outcome (case F versus G, case
I versus J).
In conclusion, we can state that the contribution of the host
environment, and more specifically its role as a source of
vascularization is critical for successful bone healing. Interestingly,
the results indicate that the lack of adequate vascularization can be
rescued by a continuous delivery of osteoprogenitor cells,
potentially in combination with osteochondrogenic growth factors.
Treatment strategies for critical size defects in a
permissive host environment
Intrigued by the results of the previous section, we wondered if
the lack of adequate vascularization could also be rescued by a
single contribution of (more optimal) initial conditions. Or, from
another perspective, whether the initial conditions that were
insufficient to result in successful bone healing in a compromised
environment (Table S1), would be able to stimulate the bone
regeneration process more in a permissive host environment. In
order to answer this question, we use the model in which the
fracture callus is partially supplied by blood vessels from the
overlying muscle (case B, Figure S3) since this environment is not
as compromised as the standard compromised condition (Table
S1) but nevertheless results in the formation of a non-union
without additional cells or growth factors (Figure 8, case B). We
tested three potential treatment strategies: the injection of growth
factors, the injection of cells and the injection of a combination
product. All the injections take place at day zero, making them
initial conditions (Figure 9).
According to the results of Figure 9, all the treatment strategies
yield at least the same (within 2% of intrinsic variability) or more
bone formation than a non-treated fracture in a permissive
environment. Moreover, the permissive environment is clearly
beneficial since the amount of bone formation is increased with
respect to the compromised environment for all the treatment
conditions (Table S1).
The injection of precursor cells does not significantly improve
the bone healing outcome since the vascularization of the central
callus area is still delayed, resulting in hypoxic conditions and cell
death (Figure 11). The injection of osteochondrogenic growth
factors is able to heal the critical size defect surrounded by a
muscular envelope that partially contributes to its vascularization if
the concentration is sufficiently high (Figures 9–10–11). The
mechanism of action underlying this result can be explained as
follows. The large initial concentration of growth factors will lead
to the differentiation of the osteoprogenitor cells into chondro-
cytes, which consume less oxygen than MSCs. Consequently, the
pool of oxygen-consuming MSCs is reduced thereby limiting the
oxygen consumption. As such, a large initial concentration of
growth factors makes the hypoxic area shrink, finally leading to the
successful healing of the critical size bone defect (Figure 11).
The injection of the combination product has improved the
amount of bone formation but is not as beneficial as osteochon-
drogenic growth factor injections alone (Figures 9–10–11). Indeed,
Figure 7. Schematic representation of the different boundary conditions that were applied to the critical size defect. (A) full vascular
contribution of the overlying muscle (case A, Figure 8) (B) partial vascular contribution of the overlying muscle (case B, Figure 8) (C) Dirichlet
boundary condition of osteochondrogenic growth factors (case C, Figure 8) (D) Dirichlet boundary condition of MSCs (case D, Figure 8). The origin of
the coordinate system is placed in the left bottom corner of the geometrical domain.
doi:10.1371/journal.pcbi.1003888.g007
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the growth factor concentration is not high enough to commit the
entire population of MSCs to the chondrogenic lineage. As such, a
small amount of MSCs remains undifferentiated and can continue
to proliferate and consume oxygen. Since MSCs consume more
oxygen than chondrocytes, the remaining MSC pool increases the
drop in oxygen tension and consequently cell death. As a result,
the amount of bone formation is lower than in the case of growth
factor treatment alone.
The predictions of the mathematical model are compared with
the results of the in vivo set-up where the influence of BMP-2
overexpressing periosteal cells on bone formation in large defects
was explored. Defects, treated with a collagen scaffold containing
mPDCs, thereby mimicking the initial conditions of the compu-
tational model, show little bone formation (Figure 12-B), which is
also predicted by the mathematical model (Figure 9, standard
permissive condition). Interestingly, while defects treated with
mPDCs show no presence of bone or cartilage in the center of the
defect (Figure 12-C1), large amounts of bone and the presence of
cartilage (arrow) and bone marrow are noted in the defects treated
with BMP-2 overexpressing mPDCs (Figure 12-C2, C3). Clearly,
the presence of BMP-2 enhances the bone formation process
which results in a clinical union. Similarly, the computational
model predicts that the injection of only growth factors is sufficient
to heal a large defect in a permissive environment (Figure 9,
gbc,init). Note, however, that in the experimental set-up BMP-2
overexpressing cells are implanted whereas computationally an
initial bolus injection of growth factors is simulated.
In the experimental model, the sites of bone formation are
closely associated with numerous large blood vessels (indicated in
dark brown by the CD31 staining, Figure 12-C5, C6), in contrast
to the small blood vessels observed in the center of the defects
treated with mPDCs only (Figure 12-C4). In the mathematical
model, the blood vessel formation is also closely connected to the
bone formation process (Figure 10). In the central callus area we
hypothesize that the small blood vessels observed in vivo arise
through vasculogenesis, which is not accounted for in the
mathematical model. However, since these small blood vessels
appear to be immature and not associated with bone formation,
the mathematical model does predict the correct tissue distribution
in the central callus area even in the predicted absence of small
blood vessels. As expected, no blood vessels are observed at the site
of cartilage formation (Figure 12-C5, arrow).
Figure 8. Influence of the muscle as a source for vascularization, MSCs, growth factors or a combination thereof on the bone
regeneration process. The tissue fractions are measured at post fracture day (PFD) 90. The standard condition is indicated in bold and has the
following dimensionalized parameter values for the initial conditions in the central area of the fracture callus: cm,init= 2.10
3 cells/ml, gbc,init=10 ng/ml,
cf,init= 1.10
4 cells/ml, mf,init=0.01 g/ml, ninit= 3.7%. Table S2 summarizes the tissue fractions quantitatively.
doi:10.1371/journal.pcbi.1003888.g008
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While the influence of the amount of seeded cells alone or in
combination with BMP-2 overexpression was not explored
experimentally, the computational simulations predicted an
improvement in the amount of bone formation but not a complete
healing of a large bone defect (Figure 9, cm,init and cm,init/gbc,init).
Note that in a compromised environment, a large defect will
develop into a non-union, irrespective of a growth factor treatment
(Table S1, standard compromised condition), whereas in an
environment with full vascular ingrowth from the overlying
muscle, a union will develop, irrespective of a growth factor
treatment (Figure 8, case A). As such, since the computational
predictions of the growth factor treatment in a permissive
environment reproduce the in vivo observations correctly, one
may speculate that the muscle overlying the large defect in the in
vivo set-up partially contributed to the vascularization of the
fracture callus and consequently the bone healing process. Further
characterization of the origin of the vasculature growing towards
the defect area would be required to confirm this.
From the results discussed above, we can conclude that a single
injection of osteochondrogenic growth factors is able to compen-
sate for the lack of adequate vascularization. Since a single
injection of cells fails to promote complete bridging of the critical
size defect in a permissive environment, a sequence of cellular
injections might be more appropriate strategy.
Treatment strategies for critical size defects in a
compromised host environment
Finally, we used the in silico model to optimize the treatment
strategy of the previous section for critical size defects surrounded
by a compromised host environment. As can be concluded from
Table S1, the lack of muscular contribution to the vascularization
of the fracture callus as well as of osteoprogenitor cells or growth
factors, greatly hampers the bone regeneration process and results
in the formation of a non-union. Furthermore, the initial
conditions can be tuned to improve the amount of bone formation
but are insufficient to provide complete healing of the critical size
defect (Table S1). This was attributed to the delayed vasculariza-
tion of the central callus area, leading to hypoxia and cell death. In
order to improve the limited biological potential of the fracture
callus and host environment, additional progenitor cells or growth
factors can be injected in the fracture callus. However, cellular
strategies would miss their therapeutic target if injections would
take place at day 0, since cell survival would be very limited in
these challenging hypoxic conditions. Therefore, we investigated
whether a single injection of MSCs, osteochondrogenic growth
factors or a combination thereof at a later time point would
improve the bone healing outcome, as in this way the blood vessel
network will have restored at least partially (Figure 13).
As can be seen in Figure 13, the injection of osteochondrogenic
growth factors does not improve the bone healing outcome, except
at PFD 0. This can be attributed to the increased chondrogenic
differentiation and consequently limited oxygen consumption, as
was discussed previously. At the other time points, the delay in
vascularization of the central callus area results in hypoxia and cell
death. Consequently, the injection of additional growth factors is
to no avail since there are no cells present on which they can exert
their influence. Interestingly, the time at which the MSCs or the
combination product was injected, appears to be a critical
Figure 9. Results of three types of treatment strategies in a permissive host environment where the overlying muscle partially
contributes to the vasculature of the fracture callus. The tissue fractions aremeasured at PFD 90. The standard condition is indicated in bold and
has the following dimensionalized parameter values for the initial conditions in the central area of the callus: cm,init=2.10
3 cells/ml, gbc,init=10 ng/ml,
cf,init=1.10
4 cells/ml, mf,init=0.01 g/ml, ninit=3.7%. Table S3 summarizes the tissue fractions quantitatively.
doi:10.1371/journal.pcbi.1003888.g009
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determinant for the final amount of bone formation. If the cellular
treatment is administered before PFD 35, the amount of bone is
reduced (compared to no treatment) since the additional cells
increase the oxygen consumption thereby worsening the hypoxic
conditions in the central callus area. One can notice a further
decrease of the effectiveness of the cellular treatment (cells only as
well as the combination with growth factors) for injections at PFD
7 and 14. This can be related to the oxygen tension encountered in
the central callus area at the time of injection, and the fact that this
oxygen tension evolves with time. More specifically, at PFD 0 the
oxygen tension has dropped only slightly and at PFD 28 the
vasculature is already growing into the fracture callus so that in
both cases the oxygen tension in the central callus area is able to
support the injected cells. At intermediate time points, however,
the oxygen tension is too low to support the injected cells,
explaining why injections at PFD 7 and 14 are the least effective. If
cells are administered at PFD 35, the delay of 35 days between the
occurrence of the fracture and the start of the cellular therapy
allows for a partial restoration of the blood vessel network, which
seems to be optimal for the injection of cells only. The effectiveness
of the combination product, however, continues to increase when
the treatment is further postponed (up to day 56). The non-
linearities in the predicted bone tissue fractions as a function of
time of administration, as well as the discrepancy in optimal timing
between the cellular and combination treatment can again be
explained by the evolving oxygen tension of the central callus area
which gradually increases as a function of time through a
combination of oxygen release from the active vasculature and
passive diffusion. More specifically, the average oxygen tension in
the central callus area of a large non-treated defect surrounded by
a compromised environment increases from 2.2% at 35 days, to
3% at 42 days, 3.9% at 49 days, 5.6% at 56 days and 6.2% at 63
days. At PFD 35 both the oxygen tension as well as the
osteochondrogenic growth factor concentration are low in the
central callus area so that only limited chondrogenic differentia-
tion occurs upon injection of MSCs. However, the low oxygen
tension inhibits extensive cellular proliferation (avoiding too much
oxygen consumption), resulting in a small amount of ‘‘quiescent’’
stem cells (similar to ninit=0.7%, Table S1). When the oxygen
tension in the central callus area subsequently increases to 3%, the
Figure 10. The predicted spatiotemporal evolution of fracture healing in a permissive environment after different treatments. (i)
bone matrix density (60.1 g/ml), (ii) active vasculature during fracture healing in a permissive environment after an injection of osteoprogenitor cells
(cm,init= 2.10
5 cells/ml), growth factors (gbc,init= 1.10
3 ng/ml) or a combination thereof (Figure 9).
doi:10.1371/journal.pcbi.1003888.g010
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remaining MSCs differentiate to chondrocytes and contribute to
the bone regeneration process. As such, there are two bursts of
chondrogenic differentiation which results in an increased amount
of bone formation. If the cellular administration occurs after PFD
35 the increased oxygen tension will enhance the chondrogenic
differentiation, thereby reducing or even eliminating the pool of
‘‘quiescent’’ stem cells. As such the proliferation and survival of the
newly formed chondrocytes will mainly determine the extent of the
bone formation. Since the average oxygen tension in the central
callus area is higher at PFD 56 and 63 than at PFD 49, more bone
will be formed for cellular injections in the former two cases,
compared to PFD 49.
By combining osteochondrogenic growth factors with stem cells,
all the injected MSCs will directly become chondrocytes thereby
depleting the pool of osteoprogenitor cells, irrespective of the
starting time of the treatment. Similar to the cellular treatments
started after PFD 35 the proliferation and survival of the
chondrocytes will mainly determine the extent of the bone
formation. It appears that the average oxygen tension at PFD 56
results in an optimal proliferation and survival of the chondrocytes
and hence subsequent endochondral bone formation. At PFD 63
the average oxygen tension becomes too high for optimal
chondrocytic proliferation thereby reducing the amount of bone
formation.
According to the model results, cellular injections are only
effective if delayed until a specific time point (i.e. day 35,
Figure 13) in order to allow for a partial restoration of the blood
vessel network. Note that although the cellular as well as the
Figure 11. The predicted spatiotemporal evolution of fracture healing in a permissive environment after different treatments. (i)
chondrocyte concentration (6106 cells/ml), (ii) growth factor concentration (6100 ng/ml) and (iii) oxygen tension (61%) during fracture healing in a
permissive environment after an injection of osteoprogenitor cells (cm,init= 2.10
5 cells/ml), growth factors (gbc,init= 1.10
3 ng/ml) or a combination
thereof (Figure 9). Note that the scale of the chondrocyte concentration is different from the one displayed in Figure 4.
doi:10.1371/journal.pcbi.1003888.g011
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Figure 12. Implantation of periosteal cells overexpressing the osteochondrogenic growth factor BMP-2 promotes healing of large
bone defects in mice. (A–B) Radiographic analysis (A) and mCT-based quantification (B) of bone formation in large bone defects treated with
collagen scaffolds containing periosteal cells (mPDC; n = 3) or periosteal cells overexpressing BMP2 (mPDC+BMP2; n = 5) showing the clear positive
effect of the presence of BMP2 on bone healing (*p,0.05). (C) Histological sections of defects treated with mPDC or mPDC+BMP2 at day 56 after
surgery, H&E (1–3) and CD31 (4–6) stainings are shown. All images were taken in the central region of the defect. Arrows indicate small regions of
cartilage adjacent to the newly formed bone. Scale bars: 100 mm. b: bone, bm: bone marrow, s: scaffold.
doi:10.1371/journal.pcbi.1003888.g012
Figure 13. Predicted amount of bone formation at PFD 90 in a large defect surrounded by a compromised environment as a
function of the PFD at which the treatment was initiated. The treatment consists of a single injection of cells (cm=1.10
6 cells/ml), growth
factors (gbc= 1.10
3 ng/ml) or a combination thereof. The results of injections at PFD 0 can also be found in Table S1.
doi:10.1371/journal.pcbi.1003888.g013
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combination treatment lead to an increased amount of bone
compared to no treatment (provided the injection is sufficiently
delayed), they nevertheless result in the formation of a non-union
(with a maximal amount of bone at 90 days up to 80% and 85%
respectively). As such, a single injection is insufficient and future
research should focus on an optimal sequence of injections in
order to heal critical sized defects in a compromised environments.
Discussion
This study has used an integrative in vivo - in silico approach to
investigate the occurrence of oligotrophic and atrophic non-unions
as well as to design possible treatment strategies thereof. An
extensive sensitivity analysis was performed in order to study the
complex interplay of blood vessel formation, oxygen supply,
growth factors and (osteoprogenitor) cells on the final healing
outcome in large bone defects. The results of the sensitivity
analysis indicated that the initial conditions (osteochondrogenic
growth factor, MSCs, oxygen) are necessary for the bone
regeneration process but not sufficient for complete bone healing
of a critical size defect (5 mm). They do, however, have an
important impact on the final amount of bone formation.
Interestingly, simulation results of the same oxygen model in a
small defect (0.5 mm) were found to be robust to changes in the
initial conditions [23].
Although the performed sensitivity analysis yields interesting
results, the interpretation thereof should be done carefully due to a
number of reasons. For example, the sensitivity analysis that was
performed in this study (Table S1) used a one-at-a-time (OAT)
design, where the effect of one factor is assessed by varying the
value of only that factor and keeping all other factors fixed. The
main disadvantage of this simple method is its inability to capture
interactions between factors. A simple combination of the
‘optimal’ values of initial conditions (see Table S1: the value that
for an OAT design yielded the most bone at PFD 90) indicates for
instance that a more adequate design is necessary to unravel these
(non-linear) interactions between the different parameters of the
oxygen model. Indeed, combining the ‘optimal’ initial conditions
of MSCs (cm,init), fibroblasts (cf,init), osteochondrogenic growth
factors (gbc,init) and oxygen (ninit) results in 38% of bone after 90
days which is less than for the respective ‘optimal’ initial conditions
alone. The conclusions of the sensitivity analysis are also only valid
for this specific set of parameter values since, for example, the
optimal initial oxygen tension will vary depending on the initial
stem cell concentration. Despite its limitations, the OAT-design
already indicates some interesting non-linear responses of the
model with respect to the initial MSC cell density and the oxygen
tension as well as their interactions. Future work should focus on
more complex designs, including latin hypercube design and
uniform design [41], to calculate quantitative metrics of sensitivity
and study these non-linearities and (higher-order) parameter
interactions further in order to unravel the underlying mechanisms
and define new research hypotheses.
The dynamics of all cellular variables (apart from the
endothelial cells) is described by means of continuum equations,
meaning amongst others that cell proliferation was captured by
means of a logistic growth equation. While this equation accounts
for a maximal cell density in the callus area, it does not allow to
specify an upper limit to the number of division cycles a cell (such
as an MSC) can undergo before senescence. Because of this upper
limit, in reality the amount of cells that can be obtained through
division is dependent on the original pool size whereas in the
mathematical model, a single cell can theoretically divide until the
entire callus reaches maximal cell density. The main consequence
of this limitation is that our predictions might be too optimistic in
that fracture healing might be even more challenging in reality,
because a sufficient number of cells (such as MSCs) cannot be
reached to heal the fracture. In the future we will try to implement
a description that allows to account for a limited number of
population doublings, potentially through the extension of the
agent-based description of endothelial cells to the skeletal cell
types.
Even though the predictions of the current model might be too
optimistic, all of the conditions explored in Table S1 nevertheless
resulted in the formation of a non-union. Indeed, the simulation
predicts that a murine bone defect becomes critical at 3 mm
(Figure 6) which corresponds to the experimental observation of
Zwingenberger et al. [42]. They report the creation of a persisting
femoral bone defect in nude mice when the defect size is 3 mm
[42]. The predicted value is also in the same range as other mouse
femoral critical defect sizes reported in the literature: 2 mm [43],
3.5 mm [44] and 4 mm [45]. As such, the computational
framework is able to model the occurrence of non-unions and
can be used to design several treatment strategies depending on
the host environment. In our model, a single initial (i.e. at PFD 0)
injection of osteochondrogenic growth factors at sufficiently high
concentration (gbc,init=1 mg/ml) directly into a callus surrounded
by a permissive environment resulted in complete healing of the
critical size defect (Figure 9). The beneficial effect of growth factor
delivery was also confirmed by the study of Patel et al. [46]. They
report that the BMP-2 release from gelatin microparticles
incorporated within the pores of a scaffold that was implanted
within a 8 mm rat cranial critical defect resulted in significantly
higher bone formation after 12 weeks, i.e. 37.4618.8% (test)
versus 7.867.1% (control) bone volume respectively. Similar
conclusions were made by Willett et al. who studied the influence
of recombinant human BMP-2 (rhBMP-2) delivery on tissue
regeneration in a murine composite injury model [47]. The in vivo
composite injury model consisted of a critically sized femoral bone
defect and an adjacent volumetric muscle injury in the quadriceps
(both 8 mm) [47]. They have shown that treated bone defects
without volumetric muscle loss were consistently bridged whereas
the treatment failed to promote the regeneration process in the
challenging composite injury [47]. Although care must be taken
when directly comparing these findings to our in silico results
(since the exact role of the muscle in the in vivo setting of Willett
et al. was not characterized), they do predict the same trends.
Indeed, the multiscale model predicts a successful healing in the
case of growth factor administration to a critical sized defect that is
fully or partially supplied by blood vessels from the overlying
muscle (Figure 9). In contrast, in a compromised environment
where the role of the muscle as a source of vascularization is
lacking, additional injections of growth factors, either at PFD 0
(Table S1) or at later time points (Figure 13) do not induce bony
bridging of the large bone defect.
In large bone defects not only the initial concentration of growth
factors but also the initial amount of osteoprogenitor cells might be
reduced [26,27]. Consequently, the use of stem cells for the
treatment of critical size defects is actively being pursued [48]. The
injection of MSCs in the callus area elicited an improved healing
response (although without reaching full bridging) in silico if the
environment is sufficiently vascularized to sustain the cell viability,
which according to the model meant that injections were only
effective if delayed until a certain time point (day 35 according to
Figure 13). Similar conclusions were drawn by Geris et al. who
investigated the occurrence of bone atrophic non-unions by an
integrative approach [49]. Based on the recovery of the blood
supply to the interfragmentary gap, they predicted with an in silico
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model that the injection of MSCs at three weeks post-osteotomy
would prevent the onset of an atrophic non-union which was also
confirmed by experimental results [49]. The necessity of
vascularization for successful healing of challenging critical size
defects is also substantiated by the results of Table S1 (no
contribution of the overlying muscle to the vasculature) and
Figure 9 (partial contribution of the overlying muscle to the
vasculature), where an initial injection (i.e. at PFD 0) of additional
cells in a defect that is insufficiently vascularized does not
significantly improve the bone formation outcome. As such, the
mathematical model retrieves the beneficial effect of cellular
injections in some cases, similar to the experimental observations
reported in literature [50,51], although the effectiveness is strongly
dependent on the available vasculature.
Interestingly, the model results indicate that the effectiveness of
a therapy (consisting of the injection of cells, growth factors or a
combination thereof) is dependent on the timing of the treatment
as well as the host environment. The former effect is strongly
related to the biological potential of the fracture callus at the time
the treatment is applied, while the latter potentially constitutes a
source of additional osteoprogenitor cells, growth factors or
vascularization. For example, growth factor injections at PFD 0
or at later time points in a compromised host environment lead to
only 63% and 52% of bone respectively whereas growth factor
injections at PFD 0 in a permissive environment result in the
formation of a union. In all three cases the main cause underlying
the formation of a non-union in a large defect (without treatment)
is the increased cell death in the central (hypoxic) callus area. Since
growth factor injections at PFD 0 result in increased chondrogenic
differentiation, which in turn limits the oxygen consumption and
the decrease of oxygen tension (severity of hypoxia), this treatment
increases the amount of bone formation. Note that nevertheless a
hypoxic area arises which results in the formation of a non-union.
Consequently, a permissive environment that provides additional
vascular ingrowth, improves the bone formation outcome even
further. Growth factor injections at later time points in a
compromised environment are, however, to no avail since there
are no cells left in the central callus area.
In summary, we can state that a treatment will be most
beneficial if it tackles the underlying mechanism of action causing
the hampered bone formation. Although this statement seems a
logical and intuitive design rule, the underlying mechanisms of
actions are a result of the complex non-linear, oxygen-dependent
dynamics of blood vessel formation, oxygen supply, angiogenic
growth factor production, cell differentiation, cell proliferation and
oxygen consumption. The fact that many cellular processes, like
survival, proliferation and differentiation are (non-linearly) depen-
dent on oxygen tension and that they all have a specific range of
Figure 14. Schematic overview of the complex spatiotemporal interplay between the amount of oxygen, growth factors and cells
as well as the gap size, the host environment and the administered treatments.
doi:10.1371/journal.pcbi.1003888.g014
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oxygen tension at which they are ‘optimized’ (maximally affected)
(Figures 1–2), makes it virtually impossible to intuitively predict
the resulting bone healing outcomes. Instead, it requires a rigorous
computational modelling of the governing mechanisms and
dependencies (Figure 14).
Taken all the results together, we can conclude that complete
cortical bridging of a challenging critical size defect will only occur
if growth factors, osteoprogenitor cells and vasculature are present
at the same time and place (Figure 14). Indeed, the blood vessels
will supply the necessary oxygen to ensure cellular survival
whereas the growth factors will promote the correct differentiation
cascade finally resulting in the continuation and successful
completion of the bone regeneration process. Consequently, the
most stringent factor that is lacking in a certain area or at a certain
time point will be an ideal candidate for potential treatment
strategies. For example, bone tissue engineering treatments where
a scaffold seeded with cells and osteochondrogenic growth factors
is implanted in a bone defect, should focus on a timely
vascularization in order to ensure the survival of the implanted
cells. Potential strategies of vascularization include the induction of
a Masquelet-membrane [52,53], the delivery of angiogenic growth
factors [46] as well as the in vitro creation of a pre-vascularized
construct by co-culture of osteoprogenitor cells with endothelial
cells [54]. Encouraging results were for example obtained by Patel
et al. who showed that the dual release of vascular endothelial
growth factor (VEGF) and bone morphogenetic protein-2 (BMP-2)
in a 8 mm rat cranial critical size defect enhanced the bone
formation at 4 weeks, suggesting a synergistic effect of these growth
factors during early bone regeneration [46]. Note that besides the
biological stimuli also mechanoregulatory stimuli influence the
bone formation process [36,37]. The current multiscale model
does not take this into account, meaning amongst others one
assumes that the fracture is sufficiently stabilized through external
or internal fixation such that excessive loading will not play a role
in the formation of a non-union (Supporting Text S2).
In conclusion, the multiscale oxygen model was able to capture
the essential aspects of in vivo atrophic and oligotrophic non-
unions. Interestingly, thorough model analyses assisted in under-
standing the underlying mechanisms of action, i.e. the delayed
vascularization of the central callus region resulted in harsh
hypoxic conditions, cell death and finally disrupted bone healing.
Since a timely vascularization was found to be critical for the
successful healing of large bone defects, the oxygen model was
used to design and test potential treatment strategies for both
permissive and compromised host environments. A qualitative
correspondence between the predicted outcomes of certain
treatment strategies and experimental observations was obtained,
clearly illustrating the model’s potential. Furthermore, the results
of this study demonstrate that due to the complex non-linear,
oxygen-dependent dynamics of blood vessel formation, oxygen
supply, angiogenic growth factor production, cell differentiation,
cell proliferation and oxygen consumption, it becomes virtually
impossible to determine the effectiveness of a treatment strategy
intuitively thereby underlining the importance computational
modelling tools. Moreover, the model predictions also showed
that the effectiveness of a therapy is strongly influenced by the host
environment since it can serve as a source of additional
osteoprogenitor cells, growth factors or vascularization to populate
the fracture callus and increase the biological potential thereof.
Consequently, future research should focus on extensive experi-
mental characterization as well as computational modelling of the
host environment and its interaction with potential treatment
strategies.
Supporting Information
Figure S1 Graphical representation of the initial posi-
tion of the ECs for six different simulation cases.
(TIF)
Figure S2 The predicted spatiotemporal evolution of
fracture healing in a critical sized defect (5 mm) for
different values of the diffusion coefficient of oxygen. (A–
D–G) bone matrix density (60.1 g/ml), (B–E–H) oxygen tension
(61%) and (C–F–I) active vasculature for different values of the
diffusion coefficient of oxygen (Dn): (A–B–C) 2.10
213 m2/s, (D–E–
F) 2.10211 m2/s, (G–H–I) 2.10210 m2/s (Table S1).
(TIF)
Figure S3 The predicted spatiotemporal evolution of
fracture healing in different host environments. (i) bone
matrix density (60.1 g/ml), (ii) active vasculature. (case A) the
overlying muscle fully contributes to the ingrowing vasculature,
(case B) the overlying muscle partially contributes to the ingrowing
vasculature, (case C) the overlying muscle produces growth factors
over the entire length of the gap and (case D) the overlying muscle
delivers osteoprogenitor cells over the entire length of the gap
(Figure 8).
(TIF)
Table S1 Overview of the results of the sensitivity
analysis on the initial conditions and the parameter
values describing oxygen delivery, oxygen diffusion and
oxygen consumption.
(DOCX)
Table S2 Influence of the muscle as a source for
vascularization, MSCs, growth factors or a combination
thereof on the bone regeneration process.
(DOCX)
Table S3 Results of three types of treatment strategies
in a permissive host environment where the overlying
muscle partially contributes to the vasculature of the
fracture callus.
(DOCX)
Text S1 Description of the mathematical model.
(DOCX)
Text S2 Estimation of the interfragmentary strains.
(DOCX)
Text S3 Influence of the diffusion coefficient of oxygen.
(DOCX)
Text S4 Influence of the host environment.
(DOCX)
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